A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy

[1]  Joe Y. Chang,et al.  Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. , 2020, The Lancet. Respiratory medicine.

[2]  R. Weichselbaum,et al.  Radiotherapy and Immunotherapy for Cancer: From “Systemic” to “Multisite” , 2020, Clinical Cancer Research.

[3]  R. Bell,et al.  Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance , 2019, Journal of Immunotherapy for Cancer.

[4]  L. Apetoh,et al.  The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response , 2019, Cancers.

[5]  C. Fuller,et al.  Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. , 2019, JAMA oncology.

[6]  Michael Lock,et al.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.

[7]  A. Grosu,et al.  Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries , 2019, Strahlentherapie und Onkologie.

[8]  J. Gong,et al.  Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination , 2018, Journal of Immunotherapy for Cancer.

[9]  R. Stupp,et al.  Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. , 2017, Cancer treatment reviews.

[10]  J. Soria,et al.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.

[11]  C. Drake,et al.  Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. , 2015, The Lancet. Oncology.

[12]  B. Loo,et al.  Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. , 2015, International journal of radiation oncology, biology, physics.

[13]  S. Ashley,et al.  Immunocompromised status in patients with necrotizing soft-tissue infection. , 2013, JAMA surgery.

[14]  A. Shinagare,et al.  Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management. , 2012, AJR. American journal of roentgenology.

[15]  J. Vogel,et al.  Enterocutaneous fistula associated with malignancy and prior radiation therapy. , 2010, Clinics in colon and rectal surgery.

[16]  J. Sonke,et al.  Normal Tissue Complication Probability after hypofractionation increased due to the high dose per fraction or the high total Biological Equivalent Dose? , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  Shenhong Wu,et al.  Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. , 2009, The Lancet. Oncology.

[18]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Berlin,et al.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.